Literature DB >> 33864941

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.

A-M C Dingemans1, M Früh2, A Ardizzoni3, B Besse4, C Faivre-Finn5, L E Hendriks6, S Lantuejoul7, S Peters8, N Reguart9, C M Rudin10, D De Ruysscher11, P E Van Schil12, J Vansteenkiste13, M Reck14.   

Abstract

Entities:  

Keywords:  Clinical Practice Guidelines; diagnosis; follow-up; small-cell lung cancer; treatment

Mesh：

Year:  2021        PMID： 33864941      PMCID： PMC9464246          DOI： 10.1016/j.annonc.2021.03.207

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   51.769


× No keyword cloud information.
  98 in total

1.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Authors:  A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer.

Authors:  R Arriagada; J P Pignon; T Le Chevalier
Journal:  N Engl J Med       Date:  2001-10-25       Impact factor: 91.245

Review 3.  Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Antonio Rossi; Marina Chiara Garassino; Michela Cinquini; Paola Sburlati; Massimo Di Maio; Gabriella Farina; Cesare Gridelli; Valter Torri
Journal:  Lung Cancer       Date:  2010-02-25       Impact factor: 5.705

Review 4.  Surgery for limited-stage small-cell lung cancer.

Authors:  Hayley Barnes; Katharine See; Stephen Barnett; Renée Manser
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

5.  Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer.

Authors:  Chi-Fu Jeffrey Yang; Derek Y Chan; Paul J Speicher; Brian C Gulack; Xiaofei Wang; Matthew G Hartwig; Mark W Onaitis; Betty C Tong; Thomas A D'Amico; Mark F Berry; David H Harpole
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

6.  Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.

Authors:  Fabio Gomes; Corinne Faivre-Finn; Hitesh Mistry; Andrea Bezjak; Nicolas Pourel; Pierre Fournel; Jan Van Meerbeeck; Fiona Blackhall
Journal:  Lung Cancer       Date:  2021-01-30       Impact factor: 5.705

7.  Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  A Gregor; A Cull; R J Stephens; J A Kirkpatrick; J R Yarnold; D J Girling; F R Macbeth; R Stout; D Machin
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

8.  Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

Authors:  Jonathan W Goldman; Marina Chiara Garassino; Yuanbin Chen; Mustafa Özgüroğlu; Mikhail Dvorkin; Dmytro Trukhin; Galina Statsenko; Katsuyuki Hotta; Jun Ho Ji; Maximilian J Hochmair; Oleksandr Voitko; Libor Havel; Artem Poltoratskiy; György Losonczy; Niels Reinmuth; Nikunj Patel; Peter J Laud; Norah Shire; Haiyi Jiang; Luis Paz-Ares
Journal:  Lung Cancer       Date:  2020-09-10       Impact factor: 5.705

9.  Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).

Authors:  Stephen V Liu; Martin Reck; Aaron S Mansfield; Tony Mok; Arnaud Scherpereel; Niels Reinmuth; Marina Chiara Garassino; Javier De Castro Carpeno; Raffaele Califano; Makoto Nishio; Francisco Orlandi; Jorge Alatorre-Alexander; Ticiana Leal; Ying Cheng; Jong-Seok Lee; Sivuonthanh Lam; Mark McCleland; Yu Deng; See Phan; Leora Horn
Journal:  J Clin Oncol       Date:  2021-01-13       Impact factor: 44.544

Review 10.  Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.

Authors:  A Parsons; A Daley; R Begh; P Aveyard
Journal:  BMJ       Date:  2010-01-21
View more
  30 in total

1.  Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.

Authors:  Shuwen Zhang; Jingjing Chen; Rui Zhang; Liqin Xu; Yan Wang; Zaixin Yuan; Xiaohui Hou; Jian Feng
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-06       Impact factor: 4.553

Review 2.  Update 2021: Management of Small Cell Lung Cancer.

Authors:  Sara Tariq; So Yeon Kim; Jose Monteiro de Oliveira Novaes; Haiying Cheng
Journal:  Lung       Date:  2021-11-10       Impact factor: 2.584

3.  cfDNA methylome profiling for detection and subtyping of small cell lung cancers.

Authors:  Francesca Chemi; Simon P Pearce; Alexandra Clipson; Steven M Hill; Alicia-Marie Conway; Sophie A Richardson; Katarzyna Kamieniecka; Rebecca Caeser; Daniel J White; Sumitra Mohan; Victoria Foy; Kathryn L Simpson; Melanie Galvin; Kristopher K Frese; Lynsey Priest; Jacklynn Egger; Alastair Kerr; Pierre P Massion; John T Poirier; Gerard Brady; Fiona Blackhall; Dominic G Rothwell; Charles M Rudin; Caroline Dive
Journal:  Nat Cancer       Date:  2022-08-08

4.  Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors.

Authors:  Jurij Aguiar Zdovc; Mihaela Vaupotič; Gregor Marolt; Lea Knez; Renata Režonja Kukec; Tanja Čufer; Tomaž Vovk; Iztok Grabnar
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-20       Impact factor: 3.288

5.  [Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer 
in the Elderly (2022 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-06-20

6.  Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Authors:  Birgitta Hiddinga; Karen Zwaenepoel; Annelies Janssens; Jan Van Meerbeeck; Patrick Pauwels
Journal:  Oncotarget       Date:  2022-06-01

7.  Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.

Authors:  Yuanbin Chen; Luis Paz-Ares; Niels Reinmuth; Marina Chiara Garassino; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Francesco Verderame; Libor Havel; György Losonczy; Nikolay V Conev; Katsuyuki Hotta; Jun Ho Ji; Stuart Spencer; Tapashi Dalvi; Haiyi Jiang; Jonathan W Goldman
Journal:  JTO Clin Res Rep       Date:  2022-04-26

8.  Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).

Authors:  Xiao-Long Ding; Yi-Ge Su; Liang Yu; Zhou-Lan Bai; Xue-Hong Bai; Xiao-Zhen Chen; Xia Yang; Ren Zhao; Jin-Xi He; Yan-Yang Wang
Journal:  World J Surg Oncol       Date:  2022-02-27       Impact factor: 2.754

9.  A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.

Authors:  Anifat A Elegbede; Amanda J Gibson; Andrea S Fung; Winson Y Cheung; Michelle L Dean; D Gwyn Bebb; Aliyah Pabani
Journal:  JTO Clin Res Rep       Date:  2021-10-28

10.  Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients.

Authors:  Lixia Ju; Juan Yang; Changyun Zhai; Shuizhen Chai; Zhiyi Dong; Minghua Li
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.